PFE - Pfizer Inc. (NYSE:PFE)
- Creatore Discussione poncio
- Data di inizio
-
Trading Day 19 aprile Torino - Corso Gratuito sull'investimento
Migliora la tua strategia di trading con le preziose intuizioni dei nostri esperti su oro, materie prime, analisi tecnica, criptovalute e molto altro ancora. Iscriviti subito per partecipare gratuitamente allo Swissquote Trading Day.
Per continuare a leggere visita questo LINK
klausner
Nuovo Utente
- Registrato
- 12/8/04
- Messaggi
- 1.643
- Punti reazioni
- 43
aumenta il dividendo a 0,24$
Pfizer Declares a 24-Cent Second-Quarter, 2006, Dividend
E-mail or Print this story
27 April 2006, 09:03am ET
NEW YORK, April 27 /PRNewswire-FirstCall/ -- The board of directors of Pfizer Inc today declared a 24-cent second-quarter, 2006, dividend on the company's common stock, payable June 6, 2006, to shareholders of record on May 12, 2006.
Pfizer has increased its quarterly dividend to 24 cents in both the first and second quarters of 2006 as part of a series of actions the company is taking to enhance shareholder value.
Mentioned Last Change
PFE 25.03 0.06dollars or (0.24%)
The second-quarter 2006 cash dividend will be the 270th consecutive quarterly dividend paid by Pfizer, and 2006 marks the 39th consecutive year of quarterly dividend increases for Pfizer shareholders
Pfizer Declares a 24-Cent Second-Quarter, 2006, Dividend
E-mail or Print this story
27 April 2006, 09:03am ET
NEW YORK, April 27 /PRNewswire-FirstCall/ -- The board of directors of Pfizer Inc today declared a 24-cent second-quarter, 2006, dividend on the company's common stock, payable June 6, 2006, to shareholders of record on May 12, 2006.
Pfizer has increased its quarterly dividend to 24 cents in both the first and second quarters of 2006 as part of a series of actions the company is taking to enhance shareholder value.
Mentioned Last Change
PFE 25.03 0.06dollars or (0.24%)
The second-quarter 2006 cash dividend will be the 270th consecutive quarterly dividend paid by Pfizer, and 2006 marks the 39th consecutive year of quarterly dividend increases for Pfizer shareholders
riprendiamo l'alfabetiere e studiamoci la "U" e la "V"
think it's important to recognize that pharma companies historically tend to move slowly, both up and down. They're not like a lot of these biotechs that double over six months. That's what's been so bad about pharma companies over the last few years - the slow bleed. It almost makes it more painful than a big drop - although that did happen to Merck (NYSE:MRK) - because people continue to hold onto these stocks and they never seem to recover. Look at Pfizer (NYSE: PFE): it's a mid-$20's stock, but it used to trade in the $40's. And it never had a drastic one-day drop like Merck did. That's the way I see the recover going, as well. Pharma cycles trend in a "U" shape, whereas biotechs trend in a "V." We could be at the bottom of the "U" shape right now.
Would you recommend making a shift in investment strategies from biotech to pharma?
think it's important to recognize that pharma companies historically tend to move slowly, both up and down. They're not like a lot of these biotechs that double over six months. That's what's been so bad about pharma companies over the last few years - the slow bleed. It almost makes it more painful than a big drop - although that did happen to Merck (NYSE:MRK) - because people continue to hold onto these stocks and they never seem to recover. Look at Pfizer (NYSE: PFE): it's a mid-$20's stock, but it used to trade in the $40's. And it never had a drastic one-day drop like Merck did. That's the way I see the recover going, as well. Pharma cycles trend in a "U" shape, whereas biotechs trend in a "V." We could be at the bottom of the "U" shape right now.
Would you recommend making a shift in investment strategies from biotech to pharma?
pare voglia vendere la sua divisione di farmaci generici. Un affare da 14 mld $
Colgate CEO Likes Listerine, But Plays Down Big Purchase
E-mail or Print this story
1 June 2006, 09:35am ET
Colgate-Palmolive Co.'s (CL) chief executive reiterated Thursday his fondness for Pfizer Inc.'s (PFE) Listerine mouthwash brand, but again played down Colgate's interest in buying Pfizer's entire consumer health-care unit, which is on the block.
Colgate CEO Reuben Mark was discussing the consumer-products company's acquisition strategy with investors at a Sanford C. Bernstein & Co. conference in New York. He said Colgate's "good" acquisitions typically have supported worldwide growth of a business.
"Listerine, clearly since they are about the same world market share of mouthwash as we have of toothpaste...would be a good mechanism to continue this strategy," Mark said in comments available by Webcast.
Mark quickly said he couldn't comment on "what's going on" regarding Colgate's potential in Pfizer's consumer unit, which drug giant Pfizer is considering spinning off or selling. "But historically, we have not made foolhardy economic judgments on acquisitions," Mark added.
Pfizer has indicated that, if it sells anything, it would be the entire unit and not individual consumer-product lines in a piecemeal fashion. The unit could fetch up to $14 billion, Pfizer executives have indicated.
Colgate historically hasn't made many acquisitions, Mark noted, instead choosing mainly to boost sales volume internally. He said investors shouldn't expect to be surprised by future acquisitions. What's more, Colgate doesn't " easily move" into new categories such as pharmaceuticals and over-the-counter drug products, he said. Over-the-counter products such as the Benadryl allergy medicine are part of Pfizer's consumer unit.
Colgate CEO Likes Listerine, But Plays Down Big Purchase
E-mail or Print this story
1 June 2006, 09:35am ET
Colgate-Palmolive Co.'s (CL) chief executive reiterated Thursday his fondness for Pfizer Inc.'s (PFE) Listerine mouthwash brand, but again played down Colgate's interest in buying Pfizer's entire consumer health-care unit, which is on the block.
Colgate CEO Reuben Mark was discussing the consumer-products company's acquisition strategy with investors at a Sanford C. Bernstein & Co. conference in New York. He said Colgate's "good" acquisitions typically have supported worldwide growth of a business.
"Listerine, clearly since they are about the same world market share of mouthwash as we have of toothpaste...would be a good mechanism to continue this strategy," Mark said in comments available by Webcast.
Mark quickly said he couldn't comment on "what's going on" regarding Colgate's potential in Pfizer's consumer unit, which drug giant Pfizer is considering spinning off or selling. "But historically, we have not made foolhardy economic judgments on acquisitions," Mark added.
Pfizer has indicated that, if it sells anything, it would be the entire unit and not individual consumer-product lines in a piecemeal fashion. The unit could fetch up to $14 billion, Pfizer executives have indicated.
Colgate historically hasn't made many acquisitions, Mark noted, instead choosing mainly to boost sales volume internally. He said investors shouldn't expect to be surprised by future acquisitions. What's more, Colgate doesn't " easily move" into new categories such as pharmaceuticals and over-the-counter drug products, he said. Over-the-counter products such as the Benadryl allergy medicine are part of Pfizer's consumer unit.
altro concorrente per la divisione farmaci non prescrivibili
Glaxo
GlaxoSmithKline Reportedly To Bid For Pfizer Unit
E-mail or Print this story
2 June 2006, 08:42am ET
LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK) is reportedly finalizing a bid for Pfizer Inc.'s (PFE) over-the-counter drugs division, several media outlets reported on Friday.
GlaxoSmithKline is looking to bid around $15 billion for the Pfizer unit, according to reports in the Financial Times, The Times, and others.
The FT reported that Glaxo wouldn't go higher than $16 billion, but would bid at least $14 billion. The Times report suggested Glaxo would spend up to $15 billion.
A spokesperson for GlaxoSmithKline declined to comment.
If GlaxoSmithKline succeeds, it would become the world's largest maker of nonprescription drugs.
GlaxoSmithKline shares at 1210 GMT were down 8 pence, or 0.5%, at 1488 pence in a higher London market.
U.K.-based Reckitt Benckiser (RB.LN), Germany's Bayer AG (BAY), Colgate Palmolive (CL) and Johnson & Johnson (JNJ) of the U.S. also are reportedly interested in the Pfizer division. Bids close on Tuesday, the FT said.
Pfizer has said since the start of the year that it's considering selling or spinning off its consumer-products division, which markets such popular brands as Lubriderm, Sudafed and Listerine.
Pfizer Vice Chairman David Shedlarz earlier in the year said the division, whose 2005 revenue totaled nearly $4 billion, could have a market value of more than $10 billion.
Company Web sites: www.pfizer.com/
www.gsk.com/ -London Bureau, Dow Jones Newswires; +44 (0) 20 7842 9320; AskNewswires@dowjones.com
(END) Dow Jones Newswires
Glaxo
GlaxoSmithKline Reportedly To Bid For Pfizer Unit
E-mail or Print this story
2 June 2006, 08:42am ET
LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK) is reportedly finalizing a bid for Pfizer Inc.'s (PFE) over-the-counter drugs division, several media outlets reported on Friday.
GlaxoSmithKline is looking to bid around $15 billion for the Pfizer unit, according to reports in the Financial Times, The Times, and others.
The FT reported that Glaxo wouldn't go higher than $16 billion, but would bid at least $14 billion. The Times report suggested Glaxo would spend up to $15 billion.
A spokesperson for GlaxoSmithKline declined to comment.
If GlaxoSmithKline succeeds, it would become the world's largest maker of nonprescription drugs.
GlaxoSmithKline shares at 1210 GMT were down 8 pence, or 0.5%, at 1488 pence in a higher London market.
U.K.-based Reckitt Benckiser (RB.LN), Germany's Bayer AG (BAY), Colgate Palmolive (CL) and Johnson & Johnson (JNJ) of the U.S. also are reportedly interested in the Pfizer division. Bids close on Tuesday, the FT said.
Pfizer has said since the start of the year that it's considering selling or spinning off its consumer-products division, which markets such popular brands as Lubriderm, Sudafed and Listerine.
Pfizer Vice Chairman David Shedlarz earlier in the year said the division, whose 2005 revenue totaled nearly $4 billion, could have a market value of more than $10 billion.
Company Web sites: www.pfizer.com/
www.gsk.com/ -London Bureau, Dow Jones Newswires; +44 (0) 20 7842 9320; AskNewswires@dowjones.com
(END) Dow Jones Newswires